The country is closely watching how the battle over abortion medication unfolds in federal courts. It follows a Texas judge’s decision to overturn FDA approval of the mifepristone. But there’s also growing concern over what that ruling could mean for the drug approval process in general. Amna Nawaz discussed what’s at stake with Dr. Joshua Sharfstein, the former FDA principal deputy commissioner.
When you click on our advertisements and purchase products or services through our links we earn a small commission.
Dueling decisions from federal judges over the FDA’s approval of mifepristone, one of the main medications used to provide abortions, mark the latest flash point in the fight over reproductive rights. The two decisions are the most significant abortion rulings since the U.S. Supreme Court overturned Roe v. Wade last summer. Mary Ziegler joined Geoff Bennett to discuss the legal path ahead.
On Friday, a federal judge in Texas invalidated FDA approval of mifepristone, threatening access to the most common abortion pill in the country. Earlier this week, legislatures in Idaho, Kansas and Florida moved to further restrict abortion access in those states. Sarah Varney, senior correspondent for Kaiser Health News, joins Ali Rogin to discuss the latest developments.